Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387
← catalyst calendarNCT07010159 · readout in 499 d
Sponsored by Kiniksa Pharmaceuticals International, plc (industry) · KNSA — their whole pipeline →. With Kiniksa Pharmaceuticals, GmbH.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
325estimated
Sites
62
Countries
Canada, France, Germany +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-25 | actual | When the study began enrolling |
| Primary completion | 2027-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pericarditis
- Pericarditis Acute
- Recurrent Pericarditis
Interventions
- Drug: KPL-387
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPhase 2: Time to Treatment Response by Week 24
measured From Baseline up to Week 24
Phase 3: Time to Pericarditis Recurrence
measured From Baseline in the RW Period
Long-Term Extension: Annualized rate of Pericarditis Recurrence
measured Up to 24 Months
Permalink · KNSA's whole pipeline · Catalyst calendar · Every registered study · What changed